{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T18:02:06Z","timestamp":1788372126402,"version":"build-2803163510"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Therapeutic Research"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.curtheres.2025.100776","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T18:53:38Z","timestamp":1738781618000},"page":"100776","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Efficacy of Potassium-Competitive Acid Blockers Versus Proton Pump Inhibitors for Gastric Ulcers: Bayesian and Frequentist Network Meta-Analysis With Cross-Inference Through a Quality management System"],"prefix":"10.1016","volume":"102","author":[{"given":"In Mo","family":"Yoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang-Yon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwan-Haeng","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duk-Woo","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4022-5998","authenticated-orcid":false,"given":"Hojin","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.curtheres.2025.100776_bib0001","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/0006-2952(88)90586-2","article-title":"SCH 28080 is a luminally acting, K+-site inhibitor of the gastric (H+\u202f+\u202fK+)-ATPase","volume":"37","author":"Keeling","year":"1988","journal-title":"Biochem Pharmacol"},{"issue":"10","key":"10.1016\/j.curtheres.2025.100776_bib0002","doi-asserted-by":"crossref","first-page":"5545","DOI":"10.1016\/S0021-9258(18)83580-3","article-title":"The binding of a K+ competitive ligand, 2-methyl, 8-(phenylmethoxy)imidazo(1,2-a)pyridine 3-acetonitrile, to the gastric (H+\u202f+\u202fK+)-ATPase","volume":"264","author":"Keeling","year":"1989","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.curtheres.2025.100776_bib0003","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1476-5381.1982.tb09232.x","article-title":"A study of the inhibitory effects of SCH 28080 on gastric secretion in man","volume":"76","author":"Ene","year":"1982","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.curtheres.2025.100776_bib0004","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0022-3565(25)21375-1","article-title":"Gastric antisecretory and cytoprotective activities of SCH 28080","volume":"226","author":"Long","year":"1983","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.curtheres.2025.100776_bib0005","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/0091270003261321","article-title":"Pharmacokinetic and pharmacodynamics evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers","volume":"44","author":"Yu","year":"2004","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.curtheres.2025.100776_bib0006","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/j.1440-1746.2010.06408.x","article-title":"Clinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects","volume":"25","author":"Kim","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.curtheres.2025.100776_bib0007","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4292\/wjgpt.v9.i7.63","article-title":"Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors?","volume":"9","author":"Rawla","year":"2018","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"10.1016\/j.curtheres.2025.100776_bib0008","doi-asserted-by":"crossref","DOI":"10.1177\/1756283X17745776","article-title":"Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date","volume":"11","author":"Sugano","year":"2018","journal-title":"Therap Adv Gastroenterol"},{"issue":"4","key":"10.1016\/j.curtheres.2025.100776_bib0009","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/apt.16477","article-title":"Randomised clinical trial: comparison of tegoprazan and placebo in non-erosive reflux disease","volume":"54","author":"Kim","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.curtheres.2025.100776_bib0010","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/apt.15185","article-title":"Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis","volume":"49","author":"Lee","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.curtheres.2025.100776_bib0011","doi-asserted-by":"crossref","first-page":"535","DOI":"10.5009\/gnl220055","article-title":"Triple therapy-based on tegoprazan, a new potassium-competitive acid blocker, for first-line treatment of helicobacter pylori infection: a randomized, double-blind, phase III, clinical trial","volume":"16","author":"Choi","year":"2022","journal-title":"Gut Liver"},{"issue":"6","key":"10.1016\/j.curtheres.2025.100776_bib0012","doi-asserted-by":"crossref","first-page":"709","DOI":"10.3390\/ph15060709","article-title":"Model-based prediction of acid suppression and proposal of a new dosing regimen of fexuprazan in humans","volume":"15","author":"Kim","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"6","key":"10.1016\/j.curtheres.2025.100776_bib0013","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3390\/pharmaceutics13060813","article-title":"Development of physiologically based pharmacokinetic model for orally administered fexuprazan in humans","volume":"13","author":"Jeong","year":"2021","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.curtheres.2025.100776_bib0014","doi-asserted-by":"crossref","first-page":"884","DOI":"10.5009\/gnl220457","article-title":"Efficacy and safety of fexuprazan in patients with acute and chronic gastritis","volume":"17","author":"Kim","year":"2023","journal-title":"Gut Liver"},{"issue":"10","key":"10.1016\/j.curtheres.2025.100776_bib0015","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1111\/cts.13598","article-title":"Keverprazan, a novel potassium-competitive acid blocker: multiple oral doses safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects","volume":"16","author":"Zhou","year":"2023","journal-title":"Clin Transl Sci"},{"issue":"12","key":"10.1016\/j.curtheres.2025.100776_bib0016","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1111\/apt.16959","article-title":"The efficacy and safety of keverprazan, a novel potassium-competitive acid blocker, in treating erosive oesophagitis: a phase III, randomized, double-blind multicentre study","volume":"55","author":"Chen","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.curtheres.2025.100776_bib0017","doi-asserted-by":"crossref","first-page":"e00602","DOI":"10.14309\/ctg.0000000000000602","article-title":"Efficacy and safety of Keverprazan compared with lansoprazole in the treatment of duodenal ulcer: a phase III, randomized, double-blind, multicenter trial","volume":"14","author":"Tan","year":"2023","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.curtheres.2025.100776_bib0018","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.curtheres.2025.100776_bib0019","first-page":"2","article-title":"Cochrane handbook for systematic reviews of interventions","volume":"6","author":"Higgins","year":"2021","journal-title":"Cochrane"},{"key":"10.1016\/j.curtheres.2025.100776_bib0020","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.curtheres.2025.100776_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"issue":"4","key":"10.1016\/j.curtheres.2025.100776_bib0022","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1093\/biostatistics\/kxp032","article-title":"Modeling between-trial variance structure in mixed treatment comparison","volume":"10","author":"Lu","year":"2009","journal-title":"Biostatistics"},{"key":"10.1016\/j.curtheres.2025.100776_bib0023","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Med Res Methodol"},{"issue":"11","key":"10.1016\/j.curtheres.2025.100776_bib0024","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/j.jacc.2004.01.035","article-title":"Prior convictions: bayesian approaches to the analysis and interpretation of clinical megatrials","volume":"43","author":"Diamond","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.curtheres.2025.100776_bib0025","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/insr.12232","article-title":"Modern likelihood-frequentist inference","volume":"85","author":"Pierce","year":"2017","journal-title":"Int Stat Rev"},{"issue":"8","key":"10.1016\/j.curtheres.2025.100776_bib0026","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00019053-200725080-00003","article-title":"The contrast and convergence of Bayesian and frequentist statistical approaches in pharmacoeconomic analysis","volume":"25","author":"Skrepnek","year":"2007","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.curtheres.2025.100776_bib0027","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jrsm.1045","article-title":"Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression","volume":"3","author":"White","year":"2012","journal-title":"Res Synth Methods"},{"issue":"2","key":"10.1016\/j.curtheres.2025.100776_bib0028","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res Synth Methods"},{"issue":"1","key":"10.1016\/j.curtheres.2025.100776_bib0029","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12874-021-01401-y","article-title":"Prevalence of evidence of inconsistency and its association with network structural characteristics in 201 published networks of interventions","volume":"21","author":"Veroniki","year":"2021","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"10.1016\/j.curtheres.2025.100776_bib0030","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1016\/S2468-2667(21)00302-9","article-title":"Daily steps and all-cause mortality: a meta-analysis of 15 international cohorts","volume":"7","author":"Paluch","year":"2022","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.curtheres.2025.100776_bib0031","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1097\/00042737-199412000-00012","article-title":"Efficacy and safety of lansoprazole in the treatment of gastric ulcer a multicentre study","volume":"6","author":"Florent","year":"1994","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.curtheres.2025.100776_bib0032","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2036.1995.tb00346.x","article-title":"Pantoprazole versus omeprazole in the treatment of acute gastric ulcers","volume":"9","author":"Witzel","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.curtheres.2025.100776_bib0033","first-page":"1289","article-title":"Comparison of once daily doses of lansoprazole (15, 30, and 60 mg) and placebo in patients with gastric ulcer","volume":"90","author":"Avner","year":"1995","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"10.1016\/j.curtheres.2025.100776_bib0034","first-page":"2516","article-title":"Comparison of once-daily doses of omeprazole (40 and 20 mg) and placebo in the treatment of benign gastric ulcer: a multicenter, randomized, double-blind study","volume":"91","author":"Valenzuela","year":"1996","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.curtheres.2025.100776_bib0035","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1023\/A:1018822532736","article-title":"Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD) the rabeprazole study group","volume":"43","author":"Cloud","year":"1998","journal-title":"Dig Dis Sci"},{"issue":"8","key":"10.1016\/j.curtheres.2025.100776_bib0036","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1046\/j.1365-2036.1998.00373.x","article-title":"Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer\u2013a European multicentre study. the European rabeprazole study group","volume":"12","author":"Dekkers","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.curtheres.2025.100776_bib0037","first-page":"312","article-title":"Phase III clinical trial of revaprazan (Revanex(R)) for gastric ulcer","volume":"34","author":"Chang","year":"2007","journal-title":"Korean J Gastroenterol"},{"issue":"7","key":"10.1016\/j.curtheres.2025.100776_bib0038","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00535-009-0072-4","article-title":"Randomized, parallel, double-blind comparison of the ulcer-healing effects of ilaprazole and omeprazole in the treatment of gastric and duodenal ulcers","volume":"44","author":"Ho","year":"2009","journal-title":"J Gastroenterol"},{"issue":"2","key":"10.1016\/j.curtheres.2025.100776_bib0039","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/apt.13876","article-title":"Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials","volume":"45","author":"Miwa","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.curtheres.2025.100776_bib0040","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/apt.15865","article-title":"Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer","volume":"52","author":"Cho","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.curtheres.2025.100776_bib0041","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.clinthera.2021.06.001","article-title":"Efficacy and tolerability of Evogliptin in patients with type 2 diabetes mellitus: a systematic review and meta-analysis with bayesian inference through a quality-management system","volume":"43","author":"Oh","year":"2021","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.curtheres.2025.100776_bib0042","doi-asserted-by":"crossref","first-page":"20938","DOI":"10.1038\/s41598-021-00418-z","article-title":"Antidiabetic effect of gemigliptin: a systematic review and meta-analysis of randomized controlled trials with bayesian inference through a quality management system","volume":"11","author":"Oh","year":"2021","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.curtheres.2025.100776_bib0043","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.clinthera.2023.01.005","article-title":"Blood pressure-lowering effect of fimasartan versus comparators: a cross-inference with a systematic review and meta-analysis through a quality-management system","volume":"45","author":"Oh","year":"2023","journal-title":"Clin Ther"},{"issue":"6","key":"10.1016\/j.curtheres.2025.100776_bib0044","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s11894-008-0098-4","article-title":"Pharmacology of proton pump inhibitors","volume":"10","author":"Shin","year":"2008","journal-title":"Curr Gastroenterol Rep"},{"issue":"6","key":"10.1016\/j.curtheres.2025.100776_bib0045","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1177\/1756283X16668093","article-title":"Vonoprazan-based therapy for helicobacter pylori eradication: experience and clinical evidence","volume":"9","author":"Akazawa","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.curtheres.2025.100776_bib0046","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pharmthera.2016.08.001","article-title":"Potassium-competitive acid blockers: advanced therapeutic option for acid-related diseases","volume":"168","author":"Inatomi","year":"2016","journal-title":"Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.curtheres.2025.100776_bib0047","first-page":"693","article-title":"Potassium-competitive acid blockers: present and potential utility in the armamentarium for acid peptic disorders","volume":"18","author":"Wong","year":"2022","journal-title":"Gastroenterol Hepatol (NY)"},{"issue":"11","key":"10.1016\/j.curtheres.2025.100776_bib0048","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s11894-024-00939-3","article-title":"Potassium-competitive acid blockers: current clinical use and future development","volume":"26","author":"Scarpignato","year":"2024","journal-title":"Curr Gastroenterol Rep"},{"issue":"8","key":"10.1016\/j.curtheres.2025.100776_bib0049","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/(SICI)1099-081X(1998110)19:8<493::AID-BDD129>3.0.CO;2-Z","article-title":"Pharmacokinetics of a new reversible proton pump inhibitor, YH1885, after intravenous and oral administrations to rats and dogs: hepatic first-pass effect in rats","volume":"19","author":"Han","year":"1998","journal-title":"Biopharmaceutics & Drug Disposition"},{"issue":"9","key":"10.1016\/j.curtheres.2025.100776_bib0050","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.clinthera.2012.07.004","article-title":"Bioavailability and tolerability of combination treatment with revaprazan 200 mg\u202f+\u202fitopride 150 mg: a randomized crossover study in healthy male Korean volunteers","volume":"34","author":"Choi","year":"2012","journal-title":"Clin Ther"},{"issue":"11\u201312","key":"10.1016\/j.curtheres.2025.100776_bib0051","first-page":"1640","article-title":"Pharmacodynamics of tegoprazan and revaprazan after single and multiple oral doses in healthy subjects","volume":"52","author":"Jung","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"15","key":"10.1016\/j.curtheres.2025.100776_bib0052","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/j.1440-1746.2010.06408.x","article-title":"Clinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects","volume":"25","author":"Kim","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"issue":"11\u201312","key":"10.1016\/j.curtheres.2025.100776_bib0053","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/apt.13414","article-title":"The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+ -ATPase","volume":"42","author":"Scott","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.curtheres.2025.100776_bib0054","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1124\/jpet.117.244202","article-title":"Tegoprazan, a novel potassium-competitive acid blocker to control gastric acid secretion and motility","volume":"364","author":"Takahashi","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.curtheres.2025.100776_bib0055","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/apt.13461","article-title":"Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis","volume":"43","author":"Ashida","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.curtheres.2025.100776_bib0056","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1124\/jpet.118.254904","article-title":"Effects of tegoprazan, a novel potassium-competitive acid blocker, on rat models of gastric acid\u2013related disease","volume":"369","author":"Kim","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.curtheres.2025.100776_bib0057","doi-asserted-by":"crossref","first-page":"80","DOI":"10.12793\/tcp.2019.27.2.80","article-title":"Comparison of pharmacokinetic characteristics of two tegoprazan (CJ-12420) formulations in healthy male subjects","volume":"27","author":"Hwang","year":"2019","journal-title":"Transl Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.curtheres.2025.100776_bib0058","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5009\/gnl15502","article-title":"Years of proton pump inhibitors: a comprehensive review","volume":"11","author":"Strand","year":"2017","journal-title":"Gut Liver"},{"issue":"1","key":"10.1016\/j.curtheres.2025.100776_bib0059","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5056\/jnm.2013.19.1.25","article-title":"Pharmacokinetics and pharmacodynamics of the proton pump inhibitors","volume":"19","author":"Shin","year":"2013","journal-title":"J Neurogastroenterol Motil"},{"issue":"6","key":"10.1016\/j.curtheres.2025.100776_bib0060","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/apt.15963","article-title":"Editorial: tegoprazan\u2014The newest advance in the management of acid-related diseases","volume":"52","author":"Marcus","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.curtheres.2025.100776_bib0061","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.clinthera.2021.06.007","article-title":"Effect of food on the pharmacokinetics and pharmacodynamics of a single oral dose of tegoprazan","volume":"43","author":"Han","year":"2021","journal-title":"Clin Ther"},{"issue":"7","key":"10.1016\/j.curtheres.2025.100776_bib0062","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1111\/bcp.15268","article-title":"Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole","volume":"88","author":"Yang","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.curtheres.2025.100776_bib0063","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jama.2009.261","article-title":"Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome","volume":"301","author":"Ho","year":"2009","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.curtheres.2025.100776_bib0064","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1503\/cmaj.082001","article-title":"A population-based study of the drug interaction between proton pump inhibitors and clopidogrel","volume":"180","author":"Juurlink","year":"2009","journal-title":"CMAJ"},{"issue":"4","key":"10.1016\/j.curtheres.2025.100776_bib0065","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1080\/17425255.2018.1461835","article-title":"Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine","volume":"14","author":"Rouby","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"9","key":"10.1016\/j.curtheres.2025.100776_bib0066","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.3390\/pharmaceutics13091489","article-title":"Prediction of drug-drug interaction potential of tegoprazan using physiologically based pharmacokinetic modeling and simulation","volume":"13","author":"Yoon","year":"2021","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.curtheres.2025.100776_bib0067","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.clinthera.2021.01.026","article-title":"Pharmacokinetic interactions between tegoprazan and metronidazole\/tetracycline\/bismuth and safety assessment in healthy Korean male subjects","volume":"43","author":"Jeon","year":"2021","journal-title":"Clin Ther"},{"issue":"7","key":"10.1016\/j.curtheres.2025.100776_bib0068","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.clinthera.2022.06.002","article-title":"Pharmacokinetic interactions between tegoprazan and naproxen, aceclofenac, and celecoxib in healthy Korean male subjects","volume":"44","author":"Moon","year":"2022","journal-title":"Clin Ther"},{"key":"10.1016\/j.curtheres.2025.100776_bib0069","unstructured":"Study to evaluate the efficacy and safety of DWP14012 in patients with erosive gastroesophageal reflux disease (phase 2, therapeutic exploratory study). https:\/\/clinicaltrials.gov, 2020. Accessed 13 August 2024."},{"issue":"44","key":"10.1016\/j.curtheres.2025.100776_bib0070","doi-asserted-by":"crossref","first-page":"6294","DOI":"10.3748\/wjg.v28.i44.6294","article-title":"Randomized controlled trial to evalute the efficacy and safety of fexuprazan compared with esomeprazoe in erosive esophagitis","volume":"28","author":"Lee","year":"2022","journal-title":"World J Gastroenterol"},{"issue":"11","key":"10.1016\/j.curtheres.2025.100776_bib0071","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.3390\/jcm13113262","article-title":"A phase III head-to-head study to compare the efficacy and safety of fexuprazan and esomeprazole in treating patients with erosive esophagitis","volume":"13","author":"Jeong","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.curtheres.2025.100776_bib0072","unstructured":"Study to evaluate the efficacy and safety of DWP14012 in patients with acute or chronic gastritis. https:\/\/clinicaltrials.gov, 2021. Accessed 13 August 2024."},{"issue":"16","key":"10.1016\/j.curtheres.2025.100776_bib0073","doi-asserted-by":"crossref","first-page":"884","DOI":"10.5009\/gnl220457","article-title":"Efficacy and safety of fexuprazan in patients with acute or chronic gastritis","volume":"17","author":"Kim","year":"2023","journal-title":"Gut Liver"},{"issue":"2","key":"10.1016\/j.curtheres.2025.100776_bib0074","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/apt.14818","article-title":"Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium-competitive acid blocker, in healthy male subjects","volume":"48","author":"Sunwoo","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.curtheres.2025.100776_bib0075","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11938-020-00330-x","article-title":"Acid suppressant therapy: a step forward with potassium-competitive acid blockers","volume":"19","author":"Scarpignato","year":"2021","journal-title":"Curr Treat Options Gastroenterol"},{"issue":"10","key":"10.1016\/j.curtheres.2025.100776_bib0076","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1111\/cts.13598","article-title":"Keverprazan, a novel potassium-competitive acid blocker: multiple oral doses safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects","volume":"16","author":"Zhou","year":"2023","journal-title":"Transl Sci"},{"issue":"7","key":"10.1016\/j.curtheres.2025.100776_bib0077","first-page":"502","article-title":"Embryo-fetal developmental toxicity and toxicokinetics of carenoprazan hydrochloride in rabbits","volume":"34","author":"Bin Shu","year":"2020","journal-title":"Chin J Pharmacol Toxicol"},{"issue":"7","key":"10.1016\/j.curtheres.2025.100776_bib0078","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/apt.13121","article-title":"Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects","volume":"41","author":"Jenkins","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.curtheres.2025.100776_bib0079","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1111\/apt.16959","article-title":"The efficacy and safety of keverprazan, a novel potassium-competitive acid blocker, in treating erosive oesophagitis: a phase III, randomised, double-blind multicentre study","volume":"55","author":"Chen","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.curtheres.2025.100776_bib0080","doi-asserted-by":"crossref","first-page":"e00602","DOI":"10.14309\/ctg.0000000000000602","article-title":"Efficacy and safety of keverprazan compared with lansoprazole in the treatment of duodenal ulcer: a phase III, randomized, double-blind, multicenter trial","volume":"14","author":"Tan","year":"2023","journal-title":"Clin Transl Gastroenterol"}],"container-title":["Current Therapeutic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X25000013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X25000013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T22:28:33Z","timestamp":1762122513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011393X25000013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":80,"alternative-id":["S0011393X25000013"],"URL":"https:\/\/doi.org\/10.1016\/j.curtheres.2025.100776","relation":{},"ISSN":["0011-393X"],"issn-type":[{"value":"0011-393X","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Potassium-Competitive Acid Blockers Versus Proton Pump Inhibitors for Gastric Ulcers: Bayesian and Frequentist Network Meta-Analysis With Cross-Inference Through a Quality management System","name":"articletitle","label":"Article Title"},{"value":"Current Therapeutic Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.curtheres.2025.100776","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100776"}}